Heron Therapeutics, Inc. (HRTX), headquartered in San Diego, California, is a pioneering biotechnology firm focused on developing innovative therapies for unmet medical needs in pain management and antiemetic care. The company is dedicated to optimizing patient outcomes through its robust pipeline of advanced pharmaceutical solutions, specifically tailored for individuals undergoing surgical procedures and cancer treatments. With a strong emphasis on addressing high-demand therapeutic areas, Heron Therapeutics is well-positioned to drive significant advancements in healthcare, thereby enhancing the quality of life for patients and addressing critical challenges within the medical community. Show more

Location: 100 REGENCY FOREST DRIVE, CARY, NC, UNITED STATES, 27518, Cary, NC, 27518, USA | Website: https://www.herontx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

242M

52 Wk Range

$1.00 - $2.68

Previous Close

$1.34

Open

$1.33

Volume

691,444

Day Range

$1.31 - $1.34

Enterprise Value

338.5M

Cash

43.07M

Avg Qtr Burn

N/A

Insider Ownership

0.66%

Institutional Own.

84.75%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ZYNRELEF® Vial Access Needle ("VAN") Details Post operative acute pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sustol Details Chemotherapy induced nausea and vomiting	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APONVIE™ (HTX-019) Details Nausea and vomiting	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZYNRELEF (bupivacaine and meloxicam) HTX-011 Details Post operative acute pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZYNRELEF (bupivacaine and meloxicam) HTX-011 Details Post operative acute pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cinvanti Details Chemotherapy induced nausea and vomiting	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.